clinical trial · NCT07473778
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
Gilead Sciences·—·recruiting·n = 3,000
HIV InfectionsLenacapavir InjectionEmtricitabine/tenofovir disoproxil fumarate (F/TDF)Emtricitabine/tenofovir alafenamide (F/TAF)Cabotegravir (CAB)Lenacapavir Tablet
brief summary
The goal of this observational study is to generate real-life information on the use of lenacapavir (LEN, YEZTUGO®, (YTG)) for pre-exposure prophylaxis (PrEP) across diverse clinical settings in the United States. The study will characterize how PrEP is initiated, used, and discontinued in routine clinical practice when LEN is added as PrEP option and will evaluate persistence on LEN PrEP. The primary objective of this study is to evaluate real-life persistence on LEN PrEP at Week 52 in diverse clinical settings in the United States.
started
Mar 17, 2026
primary completion
Apr 1, 2028
completion
Apr 1, 2029
last updated
Apr 3, 2026
official title
Pioneering Research to Optimize Pre-exposure Prophylaxis (PrEP) Expansion With Lenacapavir (LEN)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol